Benralizumab 30 mg
D3252C00002
Phase 3 mab terminated
Quick answer
Benralizumab 30 mg for Nasal Polyposis is a Phase 3 program (mab) at AstraZeneca with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca
- Indication
- Nasal Polyposis
- Phase
- Phase 3
- Modality
- mab
- Status
- terminated